|
|
||||||||
Eur J Cardiothorac Surg 2007;31:817-820. doi:10.1016/j.ejcts.2007.02.010
Copyright © 2007, European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved
a University of Connecticut School of Pharmacy, Storrs, CT, United States
b University of Connecticut School of Medicine, Farmington, CT, United States
c Divisions of Drug Information and Cardiology, Hartford Hospital, Hartford, CT, United States
Received 12 October 2006; received in revised form 20 December 2006; accepted 12 February 2007.
* Corresponding author. Address: Pharmacoeconomics and Outcomes Studies Group, Hartford Hospital, 80 Seymour Street, CB309, Hartford, CT 06102, United States. Tel.: +1 860 545 2096; fax: +1 860 545 2277. (Email: ccolema{at}harthosp.org).
Background: Two recent meta-analyses demonstrated that angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) reduce the risk of developing new-onset atrial fibrillation (AF) by nearly 50%. However, the ability of ACEIs or ARBs to prevent postoperative atrial fibrillation (POAF) after cardiac surgery has not been adequately evaluated. Objective: To evaluate the impact of preoperative ACEI or ARB use on the incidence of POAF after cardiac surgery. Methods: Patients undergoing coronary artery bypass grafting and/or valvular surgery from the (atrial fibrillation suppression trials II and III (AFIST II and III) randomized, controlled trials were evaluated in this cohort evaluation. Data in respect to patient demographics, surgical characteristics, medication utilization and the incidence of POAF (defined as AF lasting at least 5 min in duration documented by telemetry) were all uniformly and prospectively collected as part of AFIST II and III. Multivariate logistic regression was utilized to calculate adjusted odds ratios with 95% confidence intervals. Results: A total of 338 patients were evaluated of which 175 (51.8%) received an ACEI or ARB preoperatively and 163 (48.2%) did not. The study population was 65.7 ± 9.1 years of age, 77.8% were male, 11.2% underwent valve surgery, 3.6% had prior AF, 10.1% had heart failure and 84.0 and 37.9% received postoperative beta-blockade and prophylactic amiodarone, respectively. In total, 110 (32.5%) patients developed POAF. Upon multivariate logistic regression, the preoperative use of an ACEI or ARB was not found to be associated with a statistically significant reduction in POAF (adjusted odds ratio; 0.71, 95% CIs 0.421.20). Conclusions: Although preoperative ACEI or ARB use reduced the odds of developing POAF by 29%, this association with not found to be statistically significant. A study with approximately 600 subjects would be needed to discern if ACEIs or ARBs truly impact POAF.
Key Words: Postoperative atrial fibrillation Renin-angiotensin-system Cardiac surgery
This article has been cited by other articles:
![]() |
P. Dorian and B. N. Singh Upstream therapies to prevent atrial fibrillation Eur. Heart J. Suppl., September 1, 2008; 10(suppl_H): H11 - H31. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G. Raja ACE inhibitors as antifibrotic agents in atrial fibrillation: potential relevance in cardiac surgery Interactive CardioVascular and Thoracic Surgery, June 1, 2008; 7(3): 476 - 476. [Full Text] [PDF] |
||||
![]() |
A. Kourliouros, A. De Souza, N. Roberts, A. Marciniak, A. Tsiouris, O. Valencia, J. Camm, and M. Jahangiri Dose-related effect of statins on atrial fibrillation after cardiac surgery. Ann. Thorac. Surg., May 1, 2008; 85(5): 1515 - 1520. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. I. Paraskevas Applications of statins in cardiothoracic surgery: more than just lipid-lowering Eur. J. Cardiothorac. Surg., March 1, 2008; 33(3): 377 - 390. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |